Spanish for neuro-oncology clinic nurses — the patient who cannot understand why surgery removed the visible tumor but radiation and chemotherapy are still required, the patient on active surveillance for a tumor the team says will grow but is choosing not to treat yet, and the patient on temozolomide who is worried the medication is not working because she does not feel sick

The neuro-oncology clinic sits at the intersection of two realities that are difficult to hold simultaneously: the reality of a treatable disease and the reality of a disease that is nearly always serious. Patients arrive carrying frameworks built from prior health experiences, from what a family member went through with cancer, from what they were told in the neurosurgery recovery room, and from what they have read in the days between the biopsy result and the first oncology appointment. Those frameworks are almost always incomplete. The neuro-oncology clinic nurse’s job, often before the physician enters the room, is to understand what framework the patient has brought and to fill in the specific gaps that will determine whether the patient can participate in the treatment plan they are being asked to commit to.

For Spanish-speaking patients, those gaps compound. The vocabulary of neuro-oncology — glioblastoma, IDH mutation, gross total resection, MGMT methylation, temozolomide, the Stupp protocol — does not have common Spanish equivalents that patients encounter in daily life. The concepts are unfamiliar even in English. And the specific ways glioblastoma behaves — its infiltrative nature, the reason surgery alone is never sufficient, the reason a good surgical outcome still requires six weeks of daily radiation and chemotherapy — require explanations that go well beyond reassurance.

Roberto Solano is fifty-four years old. He has worked as a licensed electrician in Tampa, Florida, for twenty-seven years. He is compact, precise, quiet. He emigrated from Puerto Rico at twenty-one and speaks English professionally but processes medical information in Spanish. Three weeks ago he had a seizure at work — his first in his life — while pulling wire through a conduit on the third floor of an office building. His coworkers called 911. The emergency department CT showed a hyperdense lesion in the right temporal lobe. MRI with contrast showed a 3.8-centimeter ring-enhancing mass with surrounding edema. He was admitted. The neurosurgery team operated two days later. Dr. Hernández achieved gross total resection — no residual enhancement was visible on the post-operative MRI. In the recovery room, Dr. Hernández told Roberto and his wife Marta: “The surgery went very well. We got it all.” The pathology returned four days later: glioblastoma, IDH-wild-type, WHO grade 4. MGMT promoter methylation: positive. Roberto and Marta are at the neuro-oncology clinic today for the first post-surgical oncology appointment. Roberto’s question, before the clinic nurse has finished reviewing the chart, is: “Si lo sacaron todo, ¿para qué necesito la quimioterapia?”

Carmen Delgado is thirty-one years old. She has taught bilingual second grade at an elementary school in Albuquerque for six years. She speaks English and Spanish with equal fluency. Two months ago, during afternoon recess supervision, she had a seizure — her first, her only, the one that stopped her in the middle of a sentence she was saying to a student about the rules for the hopscotch court. Her aide called for help. She was transported to the emergency department. MRI showed a 2.3-centimeter non-enhancing hypointense lesion in the left supplementary motor area. Stereotactic biopsy confirmed IDH-mutant grade 2 astrocytoma, 1p/19q intact. Levetiracetam was started. She has had no further seizures. Her neurological examination is normal. She teaches school every day. Her neuro-oncology team has recommended active surveillance with quarterly MRI. Today is her first post-biopsy neuro-oncology clinic visit. She has brought printed research articles. She has a list of questions. The first one, which she holds out as she sits down, typed and underlined at the top of the page, is: “If the tumor is going to grow, why are you watching it instead of treating it?”

Gloria Vásquez is sixty-two years old. She retired from the United States Postal Service after thirty-three years as a carrier and then a supervisor on a Southside San Antonio route. She is practical, organized, and has the same relationship with her medical care that she had with her mail route: she wants to know exactly what is supposed to happen on which day and why. Eight months ago she began noticing headaches that were different from her normal headaches — more pressure, more morning-weighted. Four months ago she had an episode of word-finding difficulty while giving instructions at a family dinner. Her husband Ernesto drove her to the emergency department. MRI showed a 4.1-centimeter left parietal lesion. Surgery one week later: gross total resection confirmed, no post-operative enhancement. Pathology: glioblastoma, IDH-wild-type, WHO grade 4. MGMT promoter methylation: positive. She completed six weeks of the concurrent Stupp protocol — daily radiation to the surgical cavity and surrounding margin, daily temozolomide at 75 milligrams per square meter — finishing six weeks ago. She is now on adjuvant temozolomide, cycle 3, day 1. She arrives at the neuro-oncology clinic with Ernesto and their daughter Ana, who drove from Austin. Gloria’s concern — which she states before sitting down — is: “Yo me siento normal. No me ha dado nada. Mi vecina Francisca hizo quimioterapia para el seno y estuvo muy enferma. Perdío el pelo. No podía levantarse. Si a mí no me da nada, ¿está funcionando el medicamento?”

Roberto, Carmen, and Gloria each need something different from the clinic nurse. Roberto needs to understand the biology of a tumor that cannot be fully removed with any surgery. Carmen needs to understand the evidence behind a treatment recommendation that feels like inaction. Gloria needs to understand that the absence of the visible suffering she associated with chemotherapy is not evidence of absence of effect. Each of them needs this in Spanish, with the mechanism and the logic, not the conclusion.

Scenario 1 — Roberto Solano, 54, gross total resection of glioblastoma confirmed on post-operative MRI, presenting with the question of why radiation and chemotherapy are required when the surgeon already removed the visible tumor

The neuro-oncology clinic nurse who brings Roberto and Marta into the examination room is Sofía Reyes. She has twelve years in neuro-oncology. She has had this conversation more times than she can count, in different forms, with different patients, but always at the same moment: the first post-surgical oncology appointment, when the good news from the operating room meets the reality of what comes next. She knows that “lo sacaron todo” — he got it all — is the most clinically loaded phrase in neurosurgery, the one that lands in the patient’s mind as a finish line when the treatment team knows it is the beginning of a long road.

She reviews the chart before entering: gross total resection confirmed, no post-operative enhancement, MGMT promoter methylation positive. She knows the MGMT result is the best news in this file and that she will have a chance to give it. But she also knows that the most important thing to do first is to explain what gross total resection actually removed — and what it did not.

Sofía: “Señor Solano, bienvenido. Me llamo Sofía, soy la enfermera de clínica hoy. Antes de que entre la doctora Medina, quiero hablar con usted sobre la pregunta que me hizo afuera — sobre por qué necesita tratamiento si la cirugía salió bien. Es la pregunta correcta, y quiero darle una respuesta completa.”

(Mr. Solano, welcome. My name is Sofía, I am the clinic nurse today. Before Dr. Medina comes in, I want to talk with you about the question you asked outside — about why you need treatment if the surgery went well. It is the right question, and I want to give you a complete answer.)

Roberto: “El doctor Hernández dijo que lo sacó todo. Que no quedó nada en la resonancia.”

(Dr. Hernández said he got it all. That nothing remained on the MRI.)

What gross total resection removes — and what glioblastoma leaves behind in tissue the MRI cannot see

Sofía: “El doctor Hernández tiene razón. En la resonancia posooperatória no se ve ninguna mejora de contraste — eso significa que la parte del tumor que se ve en la resonancia quedó completamente resecada. Lo que el doctor Hernández logró es el mejor resultado quirúrgico posible para este tipo de tumor. Y tengo que explicarle por qué ese resultado, aunque sea el mejor resultado, es el comienzo del tratamiento y no el final.”

(Dr. Hernández is correct. On the post-operative MRI there is no visible contrast enhancement — that means the part of the tumor visible on MRI was completely resected. What Dr. Hernández achieved is the best surgical result possible for this type of tumor. And I need to explain to you why that result, even though it is the best result, is the beginning of treatment and not the end.)

Sofía opens the pre-operative MRI on the clinic monitor and sets it next to a diagram of the brain she uses for these conversations — a simple cross-section showing the tumor core, the surrounding edema, and the margin beyond the edema.

Sofía: “Lo que se ve en la resonancia — esta zona que brillaba con el contraste — es el centro del tumor. Es la parte más densa, donde las células están muy juntas. Eso es lo que el doctor Hernández sacó. Pero el glioblastoma no es un tumor con cápsula. No es como una pelota que se puede sacar entera. Sus células tienen la capacidad de moverse — de migrar — a lo largo de las fibras del cerebro, a tejido que en la resonancia se ve completamente normal. Esas células que ya viajaron más allá del tumor visible no se pueden ver en la imagen. No hacen que el contraste brille todavía porque son pocas células entre neuronas sanas. Pero están ahí.”

(What is visible on the MRI — this zone that brightened with contrast — is the tumor core. It is the densest part, where the cells are very close together. That is what Dr. Hernández removed. But glioblastoma is not an encapsulated tumor. It is not like a ball that can be taken out whole. Its cells have the ability to move — to migrate — along the fibers of the brain, into tissue that on the MRI appears completely normal. Those cells that have already traveled beyond the visible tumor cannot be seen on the image. They do not yet cause the contrast to brighten because they are few cells among healthy neurons. But they are there.)

Marta: “¿Cómo saben que están ahí si no se ven?”

(How do they know they are there if they cannot be seen?)

Sofía: “Porque en los estudios de patología que se han hecho por décadas — cuando se estudia el tejido del cerebro de pacientes con glioblastoma que fallecieron — las células del tumor se encuentran hasta tres y cuatro centímetros más allá del borde visible del tumor. Eso es lo que le da su característica principal a este tipo de tumor: es infiltrativo por naturaleza. No es algo que descubrimos hace poco — es una característica básica del glioblastoma que define cómo lo tratamos.”

(Because in the pathology studies that have been done for decades — when the brain tissue of patients with glioblastoma who passed away is studied — tumor cells are found up to three and four centimeters beyond the visible tumor border. That is what gives this type of tumor its main characteristic: it is infiltrative by nature. This is not something we discovered recently — it is a fundamental characteristic of glioblastoma that defines how we treat it.)

What radiation and temozolomide target — and why they come after surgery rather than instead of surgery

Roberto: “¿Y la radioterapia puede matar esas células que quedan?”

(And can radiation therapy kill those cells that remain?)

Sofía: “Es exactamente para eso que existe la radioterapia en este tratamiento. La radioterapia se dirige a la cavidad quirúrgica — donde estaba el tumor — y a una zona de uno a dos centímetros alrededor, que es la región donde es más probable que estén esas células que emigraron. Entregamos sesenta Gray — una dosis total de radiación — en treinta fracciones a lo largo de seis semanas, una por día de lunes a viernes. Al mismo tiempo, el temozolomida — que es la quimioterapia en pastillas — sensibiliza las células del tumor a la radiación: las hace más vulnerables al daño que la radiación produce. La cirugía fue esencial porque redujo la carga tumoral — cuantas más células saca el cirujano, menos células tiene que atacar el tratamiento posterior. Pero las células que quedaron son las que determinan si el tratamiento funciona. Por eso la cirugía y el tratamiento que sigue son los dos partes del mismo plan, no uno en lugar del otro.”

(That is exactly what radiation therapy exists for in this treatment. Radiation therapy is directed at the surgical cavity — where the tumor was — and a one-to-two centimeter zone around it, which is the region where those migrated cells are most likely to be. We deliver sixty Gray — a total radiation dose — in thirty fractions over six weeks, one per day Monday through Friday. At the same time, the temozolomide — which is the chemotherapy in pill form — sensitizes the tumor cells to radiation: it makes them more vulnerable to the damage that radiation produces. Surgery was essential because it reduced the tumor burden — the more cells the surgeon removes, the fewer cells the subsequent treatment has to attack. But the cells that remained are the ones that determine whether treatment works. That is why surgery and the treatment that follows are both parts of the same plan, not one instead of the other.)

Roberto is quiet for a moment. He looks at the MRI image, then at the diagram. “Entonces el doctor Hernández hizo lo que podía hacer con el tumor visible. Y esto —” he gestures at the clinic “— es para las células que no se veían.”

(So Dr. Hernández did what could be done with the visible tumor. And this — is for the cells that were not visible.)

Sofía: “Exactamente. Y hay algo más que quiero decirle, porque es una buena noticia dentro de este diagnóstico.”

(Exactly. And there is something else I want to tell you, because it is good news within this diagnosis.)

The MGMT result — what promoter methylation means in language Roberto can use

Sofía: “El resultado de laboratorio en la muestra del tumor — el MGMT — salió positivo para metilación. Le voy a explicar qué significa eso. El temozolomida funciona dañando el ADN de las células del tumor de una manera específica — añade una marca química que dice ‘este ADN tiene un error.’ Algunos tumores tienen activa una proteína — la MGMT — que puede borrar esa marca y reparar el daño, lo que le permite a las células seguir dividiéndose a pesar del medicamento. El tumor de usted tiene esa proteína apagada — metilada, en la terminología. El medicamento hace la marca. El tumor no puede borrarla. Las células no pueden repararse y mueren.”

(The lab result on the tumor sample — the MGMT — came back positive for methylation. I am going to explain what that means. Temozolomide works by damaging the tumor cells’ DNA in a specific way — it adds a chemical mark that says ‘this DNA has an error.’ Some tumors have an active protein — the MGMT — that can erase that mark and repair the damage, which allows the cells to keep dividing despite the medication. Your tumor has that protein turned off — methylated, in the terminology. The medication makes the mark. The tumor cannot erase it. The cells cannot repair themselves and they die.)

Roberto: “¿Eso es bueno?”

(Is that good?)

Sofía: “Para la respuesta al temozolomida, sí — es el mejor resultado posible en esa prueba. Significa que las probabilidades de que el medicamento funcione en su tumor son significativamente mejores que en un tumor con MGMT no metilado. La doctora Medina le va a dar todos los detalles del plan y de lo que significa en términos de pronóstico. Pero quería que tuviera esa información antes de que ella entrara.”

(For the response to temozolomide, yes — it is the best possible result on that test. It means the probability that the medication will work in your tumor is significantly better than in a tumor with unmethylated MGMT. Dr. Medina will give you all the details of the plan and what it means in terms of prognosis. But I wanted you to have that information before she came in.)

Marta reaches for Roberto’s hand. He is looking at the diagram. After a moment: “Entonces la cirugía fue el primer paso. No el último.”

(So the surgery was the first step. Not the last.)

Sofía: “Sí. Y fue un primer paso muy importante. Lo que viene ahora va a construir sobre lo que el doctor Hernández hizo.”

(Yes. And it was a very important first step. What comes now will build on what Dr. Hernández did.)

Roberto starts the Stupp protocol nine days later. He completes all thirty radiation fractions. He misses two days of concurrent temozolomide due to nausea managed with ondansetron and resumes the following day. His four-month post-treatment MRI shows no new enhancement. He continues in adjuvant temozolomide. At the twelve-month follow-up he is working part-time in an office-based electrical estimating role. He keeps the diagram Sofía drew on the paper on his refrigerator.

Scenario 2 — Carmen Delgado, 31, IDH-mutant grade 2 astrocytoma on active surveillance, presenting with the question of why the team is watching a tumor it acknowledges is going to grow instead of treating it now

The neuro-oncology clinic nurse who sees Carmen is Isabel Mora. She has worked in neuro-oncology for eight years and has followed patients across the full range of primary brain tumor diagnoses. She knows that the low-grade glioma active-surveillance conversation is one of the hardest she has. Not because the news is bad — IDH-mutant grade 2 has a fundamentally different prognosis than glioblastoma — but because the recommendation to watch and wait feels, to a healthy thirty-one-year-old who was teaching school last week and has a brain tumor diagnosis this week, like passivity in the face of a growing threat. Carmen has printed seven articles. Isabel respects this immediately.

Isabel: “Carmen, veo que trajo artículos. Me alegra. Significa que entiendo exactamente cuáles son sus preguntas y puedo darle respuestas directas. La pregunta principal que puso en la lista — por qué vigilancia activa en lugar de tratar ahora — es la más importante que puede hacer y merece una respuesta completa.”

(Carmen, I see you brought articles. I am glad. It means I understand exactly what your questions are and can give you direct answers. The main question you put on your list — why active surveillance instead of treating now — is the most important one you can ask and it deserves a complete answer.)

Carmen: “El tumor va a crecer. El doctor Aguirre me lo dijo. Si va a crecer de todas formas, ¿por qué no lo tratamos ahora cuando es pequeño?”

(The tumor is going to grow. Dr. Aguirre told me so. If it is going to grow regardless, why don’t we treat it now when it is small?)

What IDH mutation means for this tumor’s biology — and why it is not glioblastoma

Isabel: “Esa es exactamente la pregunta. Y para contestarla bien, primero necesito explicarle cómo el tumor de usted es biológicamente diferente del tipo de tumor del que probablemente está pensando cuando piensa en tumor cerebral.”

(That is exactly the question. And to answer it well, I first need to explain to you how your tumor is biologically different from the type of tumor you are probably thinking about when you think about brain tumor.)

Isabel: “El tumor de usted tiene una mutación en un gen que se llama IDH — isocitrato deshidrogenasa, que es una enzima que está involucrada en el metabolismo energético de la célula. Esa mutación cambia fundamentalmente la biología del tumor. Los tumores IDH-mutante son fundamentalmente más lentos y menos agresivos que los tumores IDH-silvestre. El glioblastoma — el tumor cerebral del que la gente ha oído hablar como el más agresivo — es IDH-silvestre. El tumor de usted es IDH-mutante. No son el mismo tumor. No tienen el mismo comportamiento. No tienen el mismo pronóstico.”

(Your tumor has a mutation in a gene called IDH — isocitrate dehydrogenase, which is an enzyme involved in cellular energy metabolism. That mutation fundamentally changes the tumor’s biology. IDH-mutant tumors are fundamentally slower and less aggressive than IDH-wild-type tumors. Glioblastoma — the brain tumor people have heard about as the most aggressive — is IDH-wild-type. Your tumor is IDH-mutant. They are not the same tumor. They do not have the same behavior. They do not have the same prognosis.)

Carmen: “¿Cuál es la diferencia en términos de tiempo?”

(What is the difference in terms of time?)

Isabel: “El glioblastoma IDH-silvestre tiene una supervivencia media de alrededor de quince meses con el tratamiento más agresivo disponible. El grado 2 IDH-mutante tiene una supervivencia general a cinco años de entre setenta y ochenta y cinco por ciento — en algunos subtipos, aún más alta. No son la misma enfermedad. Son distintos tumores que comparten el nombre “tumor cerebral” pero que se comportan de manera completamente diferente. El tumor de usted es serio — no le voy a decir que no lo es. Pero es un tumor que la ciencia entiende bien, que crece muy lentamente, y que hay evidencia clínica de cómo manejarlo de manera que preserve lo máximo posible su calidad de vida.”

(IDH-wild-type glioblastoma has a median survival of around fifteen months with the most aggressive treatment available. IDH-mutant grade 2 has a five-year overall survival of between seventy and eighty-five percent — in some subtypes, even higher. They are not the same disease. They are different tumors that share the name “brain tumor” but that behave in completely different ways. Your tumor is serious — I am not going to tell you it is not. But it is a tumor that science understands well, that grows very slowly, and there is clinical evidence about how to manage it in a way that preserves your quality of life as much as possible.)

Why the evidence does not support immediate radiation in low-risk IDH-mutant grade 2 glioma

Carmen: “Pero si crece lentamente, ¿no es mejor tratarlo ahora antes de que crezca más?”

(But if it grows slowly, isn’t it better to treat it now before it grows more?)

Isabel: “Eso es lo que los estudios clínicos que tenemos han intentado responder, y la respuesta es más matizada que ‘antes es mejor.’ Le voy a explicar lo que muestran los datos.”

(That is what the clinical studies we have have tried to answer, and the answer is more nuanced than ‘earlier is better.’ I am going to explain what the data shows.)

Isabel: “El estudio clínico más importante en este tumor — lo que se llama RTOG 9802 — comparó observación inmediata con tratamiento inmediato después de la cirugía en pacientes con glioma de bajo grado. Los pacientes de bajo riesgo — los que tienen menos de cuarenta años, función neurológica normal, reseccion casi completa, y convulsión como presentación inicial — no mostraron diferencia en supervivencia entre empezar el tratamiento inmediatamente o esperar a que el tumor creciera. Usted tiene exactamente esas características: tiene treinta y un años, examen neurológico normal, el tumor fue biopsiado pero está en un área del cerebro donde una resección completa pondría en riesgo funciones motoras importantes, y su presentación fue una convulsión con control actual con medicamento. Esas son exactamente las condiciones donde la vigilancia activa tiene el mismo resultado que el tratamiento inmediato.”

(The most important clinical study in this tumor — what is called RTOG 9802 — compared immediate observation with immediate treatment after surgery in patients with low-grade glioma. Low-risk patients — those under forty years old, normal neurological function, near-complete resection, and seizure as the initial presentation — did not show a difference in survival between starting treatment immediately or waiting for the tumor to grow. You have exactly those characteristics: you are thirty-one years old, normal neurological examination, the tumor was biopsied but is in an area of the brain where complete resection would put important motor functions at risk, and your presentation was a seizure with current control on medication. Those are exactly the conditions where active surveillance has the same outcome as immediate treatment.)

Carmen is quiet. Then: “¿Y los efectos secundarios del tratamiento?”

(And the side effects of treatment?)

The cognitive effects of radiation — and why sparing them is not the same as avoiding treatment

Isabel: “Esa es la otra parte de la ecuación, y es una parte importante. La radioterapia cerebral tiene efectos secundarios neurocognitivos que son reales y que se documentan a largo plazo — efectos en la memoria de trabajo, en la velocidad de procesamiento, en la concentración. No en todos los pacientes, no al mismo nivel, y hay formas modernas de dar radiación que reducen esos efectos. Pero existen. Y si el tratamiento inmediato no mejora la supervivencia en pacientes con sus características, la pregunta que el equipo se hace es: ¿tiene sentido exponer a Carmen, que tiene treinta y un años y enseña a niños, a esos efectos cognitivos ahora, cuando el resultado a cinco años es el mismo si esperamos?”

(That is the other part of the equation, and it is an important part. Brain radiation therapy has neurocognitive side effects that are real and are documented in the long term — effects on working memory, on processing speed, on concentration. Not in all patients, not at the same level, and there are modern ways of delivering radiation that reduce those effects. But they exist. And if immediate treatment does not improve survival in patients with your characteristics, the question the team asks is: does it make sense to expose Carmen, who is thirty-one years old and teaches children, to those cognitive effects now, when the five-year outcome is the same if we wait?)

Carmen: “¿Y qué pasa con la vigilancia? ¿Cuándo cambian la recomendación?”

(And what happens during surveillance? When do they change the recommendation?)

Isabel: “La vigilancia activa es exactamente eso — activa. Una resonancia magnética cada tres meses. En cada resonancia estamos mirando tres cosas: el tamaño del tumor, el patrón de la señal, y cualquier aparición de mejora de contraste. Si el tumor crece más de lo esperado — más de cuatro o cinco milímetros de diámetro por año — eso indica que el tumor está cambiando de comportamiento. Si aparece mejora de contraste en un tumor que antes no la tenía, eso sugiere transformación a un grado más alto — lo que indica que es momento de tratar. Si aparecen síntomas neurológicos nuevos, actuamos. La vigilancia tiene disparadores claros. Usted no va a llegar a una cita en seis meses a que le digan que el tumor transformó y que ahora hay un problema. Ese es el diseño del protocolo.”

(Active surveillance is exactly that — active. One MRI every three months. At each MRI we are looking at three things: tumor size, signal pattern, and any appearance of contrast enhancement. If the tumor grows more than expected — more than four or five millimeters in diameter per year — that indicates the tumor is changing behavior. If contrast enhancement appears in a tumor that did not previously have it, that suggests transformation to a higher grade — which indicates it is time to treat. If new neurological symptoms appear, we act. Surveillance has clear triggers. You are not going to arrive at an appointment in six months to be told the tumor transformed and now there is a problem. That is the design of the protocol.)

Carmen writes something on her printed list. Then looks up. “Entonces la vigilancia no es ‘esperamos a ver qué pasa.’ Es ‘miramos cada tres meses para saber exactamente cuándo es el momento correcto de tratar.’”

(So surveillance is not ‘we wait to see what happens.’ It is ‘we look every three months to know exactly when the right moment to treat is.’)

Isabel: “Eso es exactamente lo que es. Y en su caso, si el tumor se porta como un grado 2 IDH-mutante típico, esa vigilancia puede durar años antes de que sea momento de tratar. Con preservación de su función, de su clase, de su vida, durante esos años.”

(That is exactly what it is. And in your case, if the tumor behaves like a typical IDH-mutant grade 2, that surveillance may last years before it is time to treat. With preservation of your function, your classroom, your life, during those years.)

Carmen goes back to school the following Monday. She has her first surveillance MRI at three months: stable, no new enhancement, no growth beyond baseline measurement. At six months: no change. She keeps a calendar with her MRI dates and her school parent nights on the same sheet. At her twelve-month visit she brings Isabel a photograph of her second-graders’ first-day-of-school line, twenty-two children standing in front of her classroom door.

Scenario 3 — Gloria Vásquez, 62, glioblastoma, adjuvant temozolomide cycle 3, concerned that the medication is not working because she does not feel sick the way her neighbor felt on chemotherapy

The neuro-oncology clinic nurse who sees Gloria is Elena Cisneros. She has followed Gloria since the diagnosis four months ago and knows the whole arc of this case: the GTR that went as well as these cases can go, the MGMT methylation positive result that was the best news in a hard diagnosis, the six weeks of concurrent Stupp protocol that Gloria completed without missing a dose, the three-month MRI that showed stable post-operative changes with no new enhancement. Gloria is, by every metric, doing well. And Gloria is worried.

Elena reviews Gloria’s CBC from this morning before entering: WBC 4.2, ANC 2,100, platelets 142,000 — acceptable for cycle 3 day 1 continuation. She is cleared to proceed. She walks in with the lab results ready but puts them aside first, because what Gloria needs to hear first is not a number.

Elena: “Gloria, buenos días. ¿Cómo está?”

(Gloria, good morning. How are you?)

Gloria: “Bien. Eso es exactamente el problema. Me siento demasiado bien.”

(Well. That is exactly the problem. I feel too well.)

Elena: “Cuénteme más.”

(Tell me more.)

Where Gloria’s reference point for chemotherapy comes from — and why it does not apply to temozolomide

Gloria: “Mi vecina Francisca hizo quimioterapia para el seno hace dos años. Estuvo en cama semanas. Perdío todo el pelo. No podía comer. Ella sí sabía que algo estaba pasando en su cuerpo. Yo el mes pasado fui a una fiesta de quince. Cociné el arroz. Fui a misa el domingo. Ernesto me dice que tengo buen color. Si el medicamento estuviera funcionando, ¿no tendría que sentir algo?”

(My neighbor Francisca had chemotherapy for breast cancer two years ago. She was in bed for weeks. She lost all her hair. She could not eat. She knew something was happening in her body. I went to a quinceañera last month. I cooked the rice. I went to Sunday Mass. Ernesto says I have good color. If the medication were working, wouldn’t I have to feel something?)

Elena: “Gloria, me alegra mucho que me esté diciendo esto, porque es una de las preguntas más importantes que me puede hacer, y la respuesta es algo que tengo que explicarle bien. La quimioterapia que recibió su vecina Francisca y el temozolomida que usted toma son medicamentos completamente diferentes que funcionan de maneras completamente diferentes y que afectan el cuerpo de maneras completamente diferentes. Lo que le pasó a ella no le puede pasar a usted con este medicamento, no porque sea menos fuerte — sino porque no funciona de la misma manera.”

(Gloria, I am very glad you are telling me this, because it is one of the most important questions you can ask me, and the answer is something I need to explain to you well. The chemotherapy your neighbor Francisca received and the temozolomide you take are completely different medications that work in completely different ways and that affect the body in completely different ways. What happened to her cannot happen to you with this medication, not because it is less strong — but because it does not work the same way.)

Gloria: “¿Cómo funciona diferente?”

(How does it work differently?)

What temozolomide does at the molecular level — and why the work happens where Gloria cannot feel it

Elena: “Le voy a explicar lo que hace el temozolomida primero. El temozolomida es lo que se llama un agente alquilante — un medicamento que trabaja añadiendo una marca química muy específica al ADN de las células que se están dividiendo. Esa marca — en la terminología, se llama una metilación en una posición específica de la guanina — hace que cuando la célula del tumor intenta dividirse, no puede completar la división correctamente. El sistema de reparación del ADN de la célula detecta el daño, no puede repararlo porque el tumor de usted tiene el MGMT apagado — la proteína que borra esa marca está inactiva — y la célula activa el proceso de muerte celular programada. Ese proceso ocurre en el núcleo de las células del tumor. Es completamente invisible desde afuera.”

(I am going to explain to you what temozolomide does first. Temozolomide is what is called an alkylating agent — a medication that works by adding a very specific chemical mark to the DNA of dividing cells. That mark — in the terminology, it is called a methylation at a specific position on guanine — means that when a tumor cell tries to divide, it cannot complete the division correctly. The cell’s DNA repair system detects the damage, cannot repair it because your tumor has the MGMT turned off — the protein that erases that mark is inactive — and the cell activates the process of programmed cell death. That process occurs in the nucleus of tumor cells. It is completely invisible from the outside.)

Gloria: “El pelo de Francisca — ¿por qué le pasó eso a ella?”

(Francisca’s hair — why did that happen to her?)

Elena: “Muy buena pregunta. La quimioterapia que tomó Francisca — probablemente fue un régimen para el cáncer de seno, como ciclofosfamida o docetaxel — trabaja de una manera diferente: ataca a todas las células del cuerpo que se dividen rápidamente, no solo las células del tumor. El cabello crece rápido — los folículos pilosos se dividen rápidamente. Las células del estómago se dividen rápidamente. Las células de la médula ósea se dividen rápidamente. Ese tipo de quimioterapia las afecta a todas — por eso hay náuseas fuertes, pérdida de pelo, y cansancio severo. Es el daño a células sanas lo que produce esos síntomas. El temozolomida no funciona atacando a todas las células que se dividen rápido — su mecanismo es diferente. El pel no es el objetivo. El estómago no es el objetivo principal. Por eso usted puede cocinar el arroz y ir a misa y tener buen color. No porque el medicamento no esté funcionando.”

(Very good question. The chemotherapy Francisca took — it was probably a breast cancer regimen, like cyclophosphamide or docetaxel — works in a different way: it attacks all the cells in the body that divide rapidly, not just tumor cells. Hair grows fast — hair follicles divide rapidly. Stomach cells divide rapidly. Bone marrow cells divide rapidly. That type of chemotherapy affects all of them — that is why there is severe nausea, hair loss, and severe fatigue. It is the damage to healthy cells that produces those symptoms. Temozolomide does not work by attacking all rapidly dividing cells — its mechanism is different. Hair is not the target. The stomach is not the main target. That is why you can cook rice and go to Mass and have good color. Not because the medication is not working.)

What temozolomide does affect — and what Gloria should watch for

Ernesto: “¿Entonces no tiene ningún efecto secundario?”

(So it has no side effects?)

Elena: “Sí tiene, y quiero que Gloria los conozca bien. El efecto principal del temozolomida es en la médula ósea — donde se producen las células de la sangre. El medicamento puede reducir la producción de glóbulos blancos y plaquetas durante el ciclo. Por eso chequeamos la sangre el día veintidós y el día veintinueve de cada ciclo — para asegurarnos de que los números estén a un nivel seguro para continuar. Las náuseas son posibles — le dimos un medicamento para eso desde el principio, y me dice que las ha controlado bien. El cansancio puede aumentar a lo largo de los ciclos — es algo que vamos a monitorear. Pero la película que Gloria tiene en la cabeza — de estar en cama enferma, de perder el pelo — no corresponde al perfil de este medicamento.”

(Yes it does, and I want Gloria to know them well. The main effect of temozolomide is on the bone marrow — where blood cells are produced. The medication can reduce the production of white blood cells and platelets during the cycle. That is why we check the blood on day twenty-two and day twenty-nine of each cycle — to make sure the numbers are at a safe level to continue. Nausea is possible — we gave you a medication for that from the start, and you tell me you have controlled it well. Fatigue can increase over the cycles — that is something we will monitor. But the picture Gloria has in her mind — of being in bed sick, of losing her hair — does not correspond to this medication’s profile.)

Gloria: “¿Y cómo sé si está funcionando?”

(And how do I know if it is working?)

Elena: “La resonancia. Eso es lo que le dice a nosotros cómo está respondiendo el tumor. Su resonancia de tres meses — la que hizo después de terminar la radioterapia y antes de empezar los ciclos de temozolomida — no mostró ninguna mejora de contraste nueva. Eso es exactamente el resultado que queríamos ver. La próxima resonancia es después del ciclo seis. Seguimos monitorándola en cada ciclo con los análisis de sangre, y la resonancia nos da el resultado del tumor en el punto más importante del tratamiento. No es el pelo. No es cómo se siente en la cocina. Es la imagen.”

(The MRI. That is what tells us how the tumor is responding. Your three-month MRI — the one done after finishing radiation therapy and before starting the temozolomide cycles — showed no new contrast enhancement. That is exactly the result we wanted to see. The next MRI is after cycle six. We continue monitoring you at each cycle with the blood tests, and the MRI gives us the tumor result at the most important point in treatment. It is not the hair. It is not how you feel in the kitchen. It is the image.)

Ana, Gloria’s daughter: “¿Eso es normal — que se sienta así después de los primeros dos ciclos?”

(Is that normal — to feel this way after the first two cycles?)

Elena: “Es normal para el temozolomida en ciclos tempranos, sí. El cansancio puede aumentar en ciclos cuatro, cinco, seis — lo que es acumulativo. Pero lo que describe Gloria ahora — que fue a una quinceañera, coci nó el arroz, tiene buen color — eso no es una señal de alarma. Es una señal de que su cuerpo está tolerando el medicamento como queríamos.”

(It is normal for temozolomide in early cycles, yes. Fatigue can increase in cycles four, five, six — which is cumulative. But what Gloria describes now — that she went to a quinceañera, cooked rice, has good color — that is not a warning sign. It is a sign that her body is tolerating the medication as we wanted.)

Gloria: “Entonces ‘me siento bien’ es una buena noticia, no una mala.”

(So ‘I feel well’ is good news, not bad news.)

Elena: “En este medicamento, sí. El trabajo lo está haciendo adentro, donde no se siente. Y su análisis de esta mañana está bien — empezamos el ciclo tres hoy.”

(With this medication, yes. The work is being done inside, where it is not felt. And your labs this morning are fine — we start cycle three today.)

Gloria completes all six adjuvant cycles. She attends her granddaughter’s third birthday between cycle four and cycle five, brings a lemon cake she baked herself. Her post-cycle-six MRI shows continued stable post-operative changes, no new enhancement. She is enrolled in the q-3-month surveillance protocol. At the twelve-month post-surgery point, she remains with no evidence of progression. When her neighbor Francisca asks how the chemotherapy is going, Gloria tells her: “Diferente a la tuya — no me da nada, y eso es bueno.”

Six phrases the neuro-oncology clinic nurse needs in Spanish

The neuro-oncology clinic manages patients across dramatically different disease states — from the glioblastoma patient who needs to understand the treatment continues despite a good surgical outcome, to the low-grade glioma patient who needs to understand that watchful waiting is evidence-based rather than passive, to the patient on oral chemotherapy who needs to understand that the absence of dramatic side effects is not evidence of therapeutic failure. Each of these gaps requires a different explanation, in Spanish, with the mechanism rather than just the conclusion.

Six phrases that recur across the three scenarios above:

1. On gross total resection and why treatment continues: “La cirugía sacó la parte del tumor que se ve en la resonancia. El glioblastoma no es un tumor con cápsula — sus células ya habían viajado más allá de lo visible antes de que el cirujano operara. La radioterapia y la quimioterapia apuntan a esa región donde es más probable que estén esas células. La cirugía fue el primer paso esencial. El tratamiento que sigue es el segundo paso igualmente esencial.” (Surgery removed the part of the tumor visible on MRI. Glioblastoma is not an encapsulated tumor — its cells had already traveled beyond what was visible before the surgeon operated. Radiation therapy and chemotherapy target the region where those cells are most likely to be. Surgery was the essential first step. The treatment that follows is the equally essential second step.)
2. On IDH mutation and prognosis: “El tumor que tiene usted tiene una mutación en el gen IDH. Esa mutación cambia fundamentalmente la biología del tumor — lo hace más lento y menos agresivo. El glioblastoma que usted puede haber leído es IDH-silvestre — no es el mismo tumor. El suyo tiene una supervivencia a cinco años de setenta a ochenta y cinco por ciento. Son enfermedades diferentes que comparten el nombre ‘tumor cerebral.’” (The tumor you have has a mutation in the IDH gene. That mutation fundamentally changes the tumor’s biology — makes it slower and less aggressive. The glioblastoma you may have read about is IDH-wild-type — it is not the same tumor. Yours has a five-year survival of seventy to eighty-five percent. They are different diseases that share the name ‘brain tumor.’)
3. On active surveillance rationale: “Los estudios clínicos en pacientes con sus características — menores de cuarenta años, función normal, presentación con convulsión — muestran que el resultado a cinco años es el mismo con tratamiento inmediato o con vigilancia activa. La radioterapia tiene efectos neurocognitivos a largo plazo. Preferiríamos que usted no los experimente antes de que sean necesarios.” (Clinical studies in patients with your characteristics — under forty, normal function, seizure presentation — show that the five-year outcome is the same with immediate treatment or active surveillance. Radiation therapy has long-term neurocognitive effects. We would prefer you not experience them before they are necessary.)
4. On surveillance triggers: “La vigilancia activa tiene disparadores claros: crecimiento mayor de cuatro a cinco milímetros por año, aparición de contraste en una lesión que no lo tenía, síntomas neurológicos nuevos. Si ocurre cualquiera de esos tres, actuamos. Usted no va a llegar a una cita a enterarse de que el tumor transformó. La resonancia cada tres meses existe para saber cuándo es el momento correcto de tratar, no para esperar a ver qué pasa.” (Active surveillance has clear triggers: growth greater than four to five millimeters per year, appearance of contrast in a lesion that did not have it, new neurological symptoms. If any of those three occurs, we act. You are not going to arrive at an appointment to learn that the tumor transformed. The MRI every three months exists to know when the right moment to treat is, not to wait and see what happens.)
5. On temozolomide versus traditional chemotherapy: “El temozolomida trabaja añadiendo una marca química al ADN de las células del tumor — un proceso que ocurre en el núcleo de esas células, invisible desde afuera. La quimioterapia que produce náuseas fuertes y pérdida de pelo ataca a todas las células que se dividen rápido en el cuerpo, incluyendo células sanas. El temozolomida no funciona de esa manera. Sentirse bien no significa que el medicamento no está funcionando. Significa que está tomando un medicamento que trabaja de manera diferente.” (Temozolomide works by adding a chemical mark to the DNA of tumor cells — a process that occurs in the nucleus of those cells, invisible from the outside. The chemotherapy that produces severe nausea and hair loss attacks all rapidly dividing cells in the body, including healthy cells. Temozolomide does not work that way. Feeling well does not mean the medication is not working. It means you are taking a medication that works differently.)
6. On how treatment response is measured: “La respuesta del tumor al tratamiento no se mide por cómo se siente. Se mide en la resonancia. La imagen nos dice si hay células activas, si hay crecimiento, si el tumor está respondiendo. Los análisis de sangre en los días veintidós y veintinueve de cada ciclo nos dicen cómo está tolerando el medicamento la médula ósea. Esos dos — la resonancia y los análisis — son el sistema de monitoreo. No el pel. No el estómago.” (The tumor’s response to treatment is not measured by how you feel. It is measured on the MRI. The image tells us if there are active cells, if there is growth, if the tumor is responding. The blood tests on days twenty-two and twenty-nine of each cycle tell us how the bone marrow is tolerating the medication. Those two — the MRI and the labs — are the monitoring system. Not the hair. Not the stomach.)

For nurses working across the spectrum of neuro-oncology and oncology settings, the related posts on Spanish for neurology clinic nurses (covering diagnosis disclosure, seizure medication adherence, and the family member who recorded every appointment but still cannot explain the diagnosis), Spanish for radiation oncology nurses, Spanish for oncology nurses, Spanish for hematology-oncology inpatient nurses, Spanish for inpatient palliative care nurses, and Spanish for outpatient palliative care clinic nurses cover the clinical contexts that intersect with the neuro-oncology follow-up visit.